Condition: Non-Muscle Invasive Bladder Cancer · Sponsor: CHU de Quebec-Universite Laval
This is a phase II randomized controlled clinical trial comparing standard induction BCG versus bicalutamide and standard induction BCG among patients with non-muscle invasive bladder cancer.
This description comes directly from the study's public registry record.
Paul Toren, MD,PhD,FRCSC · 418-525-4444 · paul.toren@crchudequebec.ulaval.ca
Always discuss trial participation with your own doctor first.
| London Health Sciences Centre | London, Ontario, Canada | Recruiting |
| University Health Network, Princess Margaret Cancer Centre | Toronto, Ontario, Canada | Recruiting |
| Centre intégré de santé et services sociaux de Chaudière Appalaches | Lévis, Quebec, Canada | Recruiting |
| Centre Hospitalier de l'Université De Montréal_CHUM | Montreal, Quebec, Canada | Recruiting |
| McGill University Health Centre_CUSM | Montreal, Quebec, Canada | Recruiting |
| CHU de Québec-Université Laval | Québec, Quebec, Canada | Recruiting |
| CIUSSS de l'Estrie - CHUS | Sherbrooke, Quebec, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05327647